185 related articles for article (PubMed ID: 2496486)
1. Interferon-induced resistance of tumor target cells against lysis by interleukin-2-activated killer cells.
Takagi S; Minakuchi J; Okawa H; Yata J
Tohoku J Exp Med; 1989 Feb; 157(2):131-6. PubMed ID: 2496486
[TBL] [Abstract][Full Text] [Related]
2. Interferon-gamma-treated K562 target cells distinguish functional NK cells from lymphokine-activated killer (LAK) cells.
Powell J; Stone J; Chan WC; Yang ZD; Leatherbury A; Sell KW; Wiktor-Jedrzejczak W; Ahmed-Ansari A
Cell Immunol; 1989 Feb; 118(2):250-64. PubMed ID: 2491960
[TBL] [Abstract][Full Text] [Related]
3. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and mechanism of IFN-gamma-induced protection of human tumor cells from lysis by lymphokine-activated killer cells.
de Fries RU; Golub SH
J Immunol; 1988 May; 140(10):3686-93. PubMed ID: 3129500
[TBL] [Abstract][Full Text] [Related]
5. H-2 antigen expression and sensitivity of BL6 melanoma cells to natural killer cell cytotoxicity.
Gorelik E; Gunji Y; Herberman RB
J Immunol; 1988 Mar; 140(6):2096-102. PubMed ID: 3126240
[TBL] [Abstract][Full Text] [Related]
6. Activation of natural killer cells with interleukin 2 (IL-2) and IL-12 increases perforin binding and subsequent lysis of tumour cells.
Lehmann C; Zeis M; Uharek L
Br J Haematol; 2001 Sep; 114(3):660-5. PubMed ID: 11552995
[TBL] [Abstract][Full Text] [Related]
7. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
Chang WC; Hsiao MH; Pattengale PK
Nat Immun Cell Growth Regul; 1991; 10(2):57-70. PubMed ID: 1881400
[TBL] [Abstract][Full Text] [Related]
8. Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells.
Kozlowska AK; Tseng HC; Kaur K; Topchyan P; Inagaki A; Bui VT; Kasahara N; Cacalano N; Jewett A
Cancer Immunol Immunother; 2016 Sep; 65(9):1085-97. PubMed ID: 27439500
[TBL] [Abstract][Full Text] [Related]
9. Interferon-gamma-induced alterations of monocyte susceptibility to lysis by autologous lymphokine-activated killer (LAK) cells.
Djeu JY; Blanchard DK
Int J Cancer; 1988 Sep; 42(3):449-54. PubMed ID: 3138195
[TBL] [Abstract][Full Text] [Related]
10. Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells.
Jewett A; Bonavida B
J Clin Immunol; 1995 Jan; 15(1):35-44. PubMed ID: 7759599
[TBL] [Abstract][Full Text] [Related]
11. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
Itoh K; Tilden AB; Balch CM
J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
[TBL] [Abstract][Full Text] [Related]
12. [Augmentation of cytotoxic activity by combination with interleukin 2 and interferon gamma].
Tsunoda T; Tanimura H; Yamaue H; Tani M; Iwahashi M
Nihon Gan Chiryo Gakkai Shi; 1990 Jun; 25(6):1110-8. PubMed ID: 2118938
[TBL] [Abstract][Full Text] [Related]
13. IFN-gamma treatment of K562 cells inhibits natural killer cell triggering and decreases the susceptibility to lysis by cytoplasmic granules from large granular lymphocytes.
Grönberg A; Ferm MT; Ng J; Reynolds CW; Ortaldo JR
J Immunol; 1988 Jun; 140(12):4397-402. PubMed ID: 3131433
[TBL] [Abstract][Full Text] [Related]
14. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma).
Itoh K; Shiiba K; Shimizu Y; Suzuki R; Kumagai K
J Immunol; 1985 May; 134(5):3124-9. PubMed ID: 2984283
[TBL] [Abstract][Full Text] [Related]
15. Long-term killing of natural killer-resistant target cells by interferon-alpha-, interferon-gamma-, and interleukin-2-activated natural killer cells.
Sarzotti M; Klimpel GR; Baron S
Nat Immun Cell Growth Regul; 1989; 8(2):66-75. PubMed ID: 2503715
[TBL] [Abstract][Full Text] [Related]
16. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
[TBL] [Abstract][Full Text] [Related]
17. IFN-gamma production and cytotoxicity of IL-2-activated murine NK cells are differentially regulated by MHC class I molecules.
Kubota A; Lian RH; Lohwasser S; Salcedo M; Takei F
J Immunol; 1999 Dec; 163(12):6488-93. PubMed ID: 10586040
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human NK cell and LAK cell cytotoxicity and differentiation by PGE2.
Leung KH
Cell Immunol; 1989 Oct; 123(2):384-95. PubMed ID: 2507171
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of human natural killer cell function by the combined effects of tumor necrosis factor alpha or interleukin-1 and interferon-alpha or interleukin-2.
Ostensen ME; Thiele DL; Lipsky PE
J Biol Response Mod; 1989 Feb; 8(1):53-61. PubMed ID: 2493514
[TBL] [Abstract][Full Text] [Related]
20. The functional loss of human natural killer cell activity induced by K562 is reversible via an interleukin-2-dependent mechanism.
Abrams SI; Brahmi Z
Cell Immunol; 1986 Sep; 101(2):558-70. PubMed ID: 3489541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
